Black patients show stronger response to hormone therapy for prostate cancer
Share

DURHAM, N.C. — African-American men with advanced prostate cancer might be more responsive than white men to an anti-androgen drug and steroids, according to a study led by Duke Cancer Institute researchers.

While median survival was similar for both black and white participants in the study, the findings suggests that racial determinants may factor into the degree of response in patients. This difference could help drive strategies to improve outcomes in those who respond better to the drugs.

“African-Americans have a 2.5 times greater chance of dying from prostate cancer compared to whites,” said Daniel George, M.D., director of Duke’s Prostate & Urologic Cancer program, who presented the findings at the 2018 annual meeting of the American Society of Clinical Oncology in Chicago.

“Our study provides prospective evidence that there might be inherited genes that could affect treatment response and track with African ancestry in prostate cancer patients,” George said. “We need to look closely at the underlining genetic differences that associate with treatment response and build on that to improve survival for these patients.”

George and colleagues enrolled 50 black men and 50 white men in a prospective, multi-center study. All participants had metastatic, recurrent prostate cancer and

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD